128 related articles for article (PubMed ID: 8032305)
1. The feasibility of radioimmunotherapy of head and neck cancer.
Gerretsen M; Quak JJ; Brakenhoff RH; Snow GB; van Dongen GA
Eur J Cancer B Oral Oncol; 1994; 30B(2):82-7. PubMed ID: 8032305
[TBL] [Abstract][Full Text] [Related]
2. Radioimmunotherapy of human head and neck squamous cell carcinoma xenografts with 131I-labelled monoclonal antibody E48 IgG.
Gerretsen M; Schrijvers AH; van Walsum M; Braakhuis BJ; Quak JJ; Meijer CJ; Snow GB; van Dongen GA
Br J Cancer; 1992 Sep; 66(3):496-502. PubMed ID: 1520586
[TBL] [Abstract][Full Text] [Related]
3. 186Re-labeled monoclonal antibody E48 immunoglobulin G-mediated therapy of human head and neck squamous cell carcinoma xenografts.
Gerretsen M; Visser GW; van Walsum M; Meijer CJ; Snow GB; van Dongen GA
Cancer Res; 1993 Aug; 53(15):3524-9. PubMed ID: 8339258
[TBL] [Abstract][Full Text] [Related]
4. High dose rhenium-186-labeling of monoclonal antibodies for clinical application: pitfalls and solutions.
van Gog FB; Visser GW; Stroomer JW; Roos JC; Snow GB; van Dongen GA
Cancer; 1997 Dec; 80(12 Suppl):2360-70. PubMed ID: 9406684
[TBL] [Abstract][Full Text] [Related]
5. Complete ablation of small squamous cell carcinoma xenografts with 186Re-labeled monoclonal antibody E48.
Gerretsen M; Visser GW; Brakenhoff RH; van Walsum M; Snow GB; van Dongen GA
Cell Biophys; 1994; 24-25():135-42. PubMed ID: 7736517
[TBL] [Abstract][Full Text] [Related]
6. Labeling of monoclonal antibodies with rhenium-186 using the MAG3 chelate for radioimmunotherapy of cancer: a technical protocol.
Visser GW; Gerretsen M; Herscheid JD; Snow GB; van Dongen G
J Nucl Med; 1993 Nov; 34(11):1953-63. PubMed ID: 8229241
[TBL] [Abstract][Full Text] [Related]
7. Monoclonal antibodies labeled with rhenium-186 using the MAG3 chelate: relationship between the number of chelated groups and biodistribution characteristics.
van Gog FB; Visser GW; Klok R; van der Schors R; Snow GB; van Dongen GA
J Nucl Med; 1996 Feb; 37(2):352-62. PubMed ID: 8667076
[TBL] [Abstract][Full Text] [Related]
8. Radioimmunotherapy of head and neck cancer xenografts using 131I-labeled antibody L19-SIP for selective targeting of tumor vasculature.
Tijink BM; Neri D; Leemans CR; Budde M; Dinkelborg LM; Stigter-van Walsum M; Zardi L; van Dongen GA
J Nucl Med; 2006 Jul; 47(7):1127-35. PubMed ID: 16818947
[TBL] [Abstract][Full Text] [Related]
9. Radioimmunodetection and radioimmunotherapy of head and neck cancer.
Börjesson PK; Postema EJ; de Bree R; Roos JC; Leemans CR; Kairemo KJ; van Dongen GA
Oral Oncol; 2004 Sep; 40(8):761-72. PubMed ID: 15288829
[TBL] [Abstract][Full Text] [Related]
10. Radioimmunoscintigraphy and biodistribution of technetium-99m-labeled monoclonal antibody U36 in patients with head and neck cancer.
de Bree R; Roos JC; Quak JJ; den Hollander W; Snow GB; van Dongen GA
Clin Cancer Res; 1995 Jun; 1(6):591-8. PubMed ID: 9816020
[TBL] [Abstract][Full Text] [Related]
11. Perspectives of combined radioimmunotherapy and anti-EGFR antibody therapy for the treatment of residual head and neck cancer.
van Gog FB; Brakenhoff RH; Stigter-van Walsum M; Snow GB; van Dongen GA
Int J Cancer; 1998 Jul; 77(1):13-8. PubMed ID: 9639387
[TBL] [Abstract][Full Text] [Related]
12. Progress in radioimmunotherapy of head and neck-cancer (review).
Vandongen G; Brakenhoff R; Debree R; Gerretsen M; Quak J; Snow G
Oncol Rep; 1994 Jan; 1(1):259-64. PubMed ID: 21607350
[TBL] [Abstract][Full Text] [Related]
13. Selection of monoclonal antibody E48 IgG or U36 IgG for adjuvant radioimmunotherapy in head and neck cancer patients.
de Bree R; Roos JC; Plaizier MA; Quak JJ; van Kamp GJ; den Hollander W; Snow GB; van Dongen GA
Br J Cancer; 1997; 75(7):1049-60. PubMed ID: 9083342
[TBL] [Abstract][Full Text] [Related]
14. MAb U36, a novel monoclonal antibody successful in immunotargeting of squamous cell carcinoma of the head and neck.
Schrijvers AH; Quak JJ; Uyterlinde AM; van Walsum M; Meijer CJ; Snow GB; van Dongen GA
Cancer Res; 1993 Sep; 53(18):4383-90. PubMed ID: 8364934
[TBL] [Abstract][Full Text] [Related]
15. Superior localisation and imaging of radiolabelled monoclonal antibody E48 F(ab')2 fragment in xenografts of human squamous cell carcinoma of the head and neck and of the vulva as compared to monoclonal antibody E48 IgG.
Gerretsen M; Quak JJ; Suh JS; van Walsum M; Meijer CJ; Snow GB; van Dongen GA
Br J Cancer; 1991 Jan; 63(1):37-44. PubMed ID: 1989663
[TBL] [Abstract][Full Text] [Related]
16. Biodistribution of radiolabeled monoclonal antibody E48 IgG and F(ab')2 in patients with head and neck cancer.
de Bree R; Roos JC; Quak JJ; den Hollander W; Wilhelm AJ; van Lingen A; Snow GB; Dongen GA
Clin Cancer Res; 1995 Mar; 1(3):277-86. PubMed ID: 9815983
[TBL] [Abstract][Full Text] [Related]
17. Clinical imaging of head and neck cancer with technetium-99m-labeled monoclonal antibody E48 IgG or F(ab')2.
de Bree R; Roos JC; Quak JJ; den Hollander W; van den Brekel MW; van der Wal JE; Tobi H; Snow GB; van Dongen GA
J Nucl Med; 1994 May; 35(5):775-83. PubMed ID: 8176458
[TBL] [Abstract][Full Text] [Related]
18. Combined treatment of the experimental human papilloma virus-16-positive cervical and head and neck cancers with cisplatin and radioimmunotherapy targeting viral E6 oncoprotein.
Harris M; Wang XG; Jiang Z; Phaeton R; Koba W; Goldberg GL; Casadevall A; Dadachova E
Br J Cancer; 2013 Mar; 108(4):859-65. PubMed ID: 23385729
[TBL] [Abstract][Full Text] [Related]
19. [Monoclonal antibodies. An approach to diagnosis and treatment of micrometastases].
Bier H
HNO; 1994 May; 42(5):255-6. PubMed ID: 8050912
[No Abstract] [Full Text] [Related]
20. High-quality 124I-labelled monoclonal antibodies for use as PET scouting agents prior to 131I-radioimmunotherapy.
Verel I; Visser GW; Vosjan MJ; Finn R; Boellaard R; van Dongen GA
Eur J Nucl Med Mol Imaging; 2004 Dec; 31(12):1645-52. PubMed ID: 15290121
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
